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With the use of real-time PCR, we developed and evaluated a rapid, sensitive, specific, and reproducible
method for the detection of Epstein-Barr virus (EBV) DNA in plasma samples. This method allowed us to
screen plasma and serum samples over a range between 100 and 107 copies of DNA per ml using two sample
preparation methods based on absorption. A precision study yielded an average coefficient of variation for both
methods of less than 12%, with a coefficient of regression for the standard curve of a minimum of 0.98. We
detected EBV DNA in 19.2% of plasma samples from immunosuppressed solid-organ transplant patients
without symptoms of EBV infections with a mean load of 440 copies per ml. EBV DNA could be detected in all
transplant patients diagnosed with posttransplant lymphoproliferative disorder, with a mean load of 544,570
copies per ml. No EBV DNA could be detected in healthy individuals in nonimmunosuppressed control groups
and a mean of 6,400 copies per ml could be detected in patients with infectious mononucleosis. Further studies
revealed that the inhibitory effect of heparinized plasma could be efficiently removed by use of an extraction
method with Celite as the absorbent.
Epstein-Barr virus (EBV) is the etiological agent of infec-
tious mononucleosis (IM) and is also etiologically associated
with Burkitt’s lymphoma and nasopharyngeal carcinoma. Usu-
ally, the virus produces a mild and self-limiting primary infec-
tion in childhood. However, as a gamma herpesvirus, it persists
for life by a combination of latency in B lymphocytes and
chronic replication in oropharyngeal epithelial cells. A serious
complication after allogeneic bone marrow or solid-organ
transplantation is the development of EBV-related posttrans-
plant lymphoproliferative disorder (PTLD) due to immuno-
suppressive therapy (5, 8). The condition can be rapidly fatal if
it is not diagnosed and treated in an early stage.
Recently, it has been observed that there is a relation be-
tween PTLD and the EBV load in plasma or infected periph-
eral blood lymphocytes, as measured by semiquantitative or
competitive PCR assays (3–7, 12, 14, 15). With the advent of
real-time TaqMan quantitation and improved sample prepa-
ration techniques, the whole process from sample retrieval to
quantitative result can be reduced. Furthermore, the dynamic
range in which samples can be analyzed quantitatively without
dilution has improved considerably (7, 9, 10).
In this paper, we describe the validation of a TaqMan-based
assay for the quantitation of EBV DNA in plasma. The assay
is based on the linearity of the TaqMan assay, takes into ac-
count intra- and interassay variability as well as detection lim-
its, and can be performed in a routine setting, providing quan-
titative results within less than 6 h. Furthermore, we have
evaluated two different extraction methods, not only for
EDTA-treated plasma but also for heparin-treated plasma be-
cause heparin is known to be inhibitory for PCRs (13, 16).
MATERIALS AND METHODS
Patients and samples. Serum samples from patients with clinical suspicion of
a primary EBV infection (IM; n 5 22) and a serological profile positive for an
immunoglobulin M response to the variable capsid antigen and negative for
anti-EBV nuclear antigen were used for this analysis. These samples were kindly
provided by Peter Schroder (Groningen Public Health Laboratory). Plasma
samples from bone marrow (n 5 5) and solid-organ (n 5 5) transplant patients
who were diagnosed clinically and histologically with EBV-related PTLD were
also enrolled in the present evaluation study. Samples were taken before the start
of treatment (including before the start of reduction of immunosuppressive
treatment) was initiated. Lymph node biopsy specimens were also obtained from
these patients, and the diagnosis was confirmed with the EBER probe. Further-
more, samples from a cohort of randomly selected, EBV-seropositive, solid-
organ transplant recipients (kidney, heart, and liver; n 5 109) were included for
cross-sectional analysis. These patients had no EBV-related disease and were
routinely screened for hepatitis markers. Samples from healthy individuals and
blood donors (n 5 100) without any sign of IM or PTLD were used as a control
group. From all patients, EDTA-treated plasma samples were aliquoted and
frozen at 280°C within 2 h after collection. Only serum was available from the
22 patients with a primary EBV infection.
Nucleic acid extraction. For the isolation of EBV DNA from plasma or serum
samples, two protocols were used. The first protocol was essentially based on the
method described by Boom and coworkers (1). Briefly, 100 ml of plasma was
added to 1 ml of buffer 1 (120 g of guanidinium isothiocyanate in 100 ml of 0.1
M Tris [pH 6.4], 22 ml of 0.2 M EDTA [pH 8.0], 2.6 g of Triton X-100). After
the addition of 50 ml of Celite solution, the mixture was incubated for 10 min at
room temperature and was subsequently centrifuged for 10 s at full speed in a
tabletop centrifuge. The pellet was washed twice with buffer 2 (identical to buffer
1 but without Triton X-100 solution and EDTA), twice with 70% ethanol, and
once with acetone. The silica pellet was dried at room temperature in a vacuum
exsiccator for 10 min, after which the DNA was eluted from the silica by adding
100 ml of RNase- and DNase-free water and was incubated for 10 min at 56°C.
After centrifugation at 12,000 3 g for 2 min, the supernatant contained the DNA
and was ready for use.
The second and commercially available protocol was essentially based on the
High Pure Viral Nucleic Acid kit protocol (Roche Diagnostics, Almere, The
Netherlands). To compare this method directly with the procedure described
above, a 100-ml plasma sample is added to the mixture provided with the kit, and
finally, the same volume of 100 ml is eluted. Briefly, a 100-ml plasma sample was
added to 100 ml of 6 M guanidine-HCl–10 mM urea–10 mM Tris-HCl–20%
(vol/vol) Triton X-100 supplemented with carrier RNA and 800 mg of proteinase
K. After incubation for 10 min at 72°C, 50 ml of isopropanol was added and the
mixture was transferred to a High Pure filter tube combined with a collection
tube. The filter tube was centrifuged at 12,000 3 g for 1 min in a standard
tabletop centrifuge at room temperature. The filter was washed twice with 450 ml
of buffer (20 mM NaCl and 2 mM Tris-HCl [pH 7.5] in ethanol). After placement
of a new collection tube under the filter, 100 ml of RNase- and DNase-free water
was added to elute the DNA. To reduce the detection level of the assay, the input
and elution volumes compared to those used in the original procedure can be
changed; that is, the input volume can be increased to 200 ml of plasma and the
elution volume can be decreased to 50 ml.
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Real-time TaqMan assay. The PCR primers for the TaqMan assay were
selected from the EBV DNA genome and encode the nonglycosylated mem-
brane protein BNRF1 p143 (2, 11). The forward and reverse primers and the
probe were designed with Primer Express software (PE Biosystems, Nieuwerkerk
aan de IJssel, The Netherlands) and generated a DNA product of 74 bp. The
primers used were the EBV p143 forward primer (59-GGA.ACC.TGG
.TCA.TCC.TTG.C and the EBV p143 reverse primers (59-ACG.TGC.ATG
.GAC.CGG.TTA.AT), which were synthesized at Isogen Biosciences (Maarssen,
The Netherlands). A fluorogenic probe (59-CGC.AGG.CAC.TCG.TAC
.TGC.TCG.CT) was synthesized by PE Biosystems with a FAM reporter mole-
cule attached to the 59 end and a TAMRA quencher linked at the 39 end. The
PCR amplification was performed in a 50-ml volume containing 23 TaqMan
universal master mixture, 45 pmol of forward primer per ml, 2.5 pmol of reverse
primer, 5 pmol of the TaqMan probe, and 10 ml of isolated DNA. All reactions
were performed in duplicate. After preparation of the reaction tubes, the whole
plate holder was centrifuged at 1,000 3 g for 1 min at room temperature in a
swingout rotor (Hettich, Rotina 48R; Tuttlingen, Germany) to remove small air
bubbles in the vessels. The amplification and detection were performed with an
ABI Prism 7700 Sequence Detection System (PE Biosystems). After incubation
for 2 min at 50°C with uracil N9-glycosylase to inactivate possible PCR contam-
inants from former reactions, the reaction tube was incubated for 10 min at 95°C
to inactivate the uracil N9-glycosylase and to release the activity of the AmpliTaq
Gold DNA polymerase. The PCR cycling program consisted of 42 two-step
cycles of 15 s at 95°C and 60 s at 60°C. Real-time measurements were taken, and
a threshold cycle (Ct) value for each sample was calculated by determining the
point at which the fluorescence exceeded a threshold limit of 0.04. Each run
contained several negative controls (no template), a positive control containing
a known EBV copy number based on a standard for which the EBV copy number
was counted by electron microscopy (EBV EM standard), and a standard dilu-
tion curve for plasmid DNA containing the PCR product as an insert (see below).
Each specimen was run in duplicate and was considered positive only if both
replications were above the threshold limit.
Standardization. For standardization of the assay, a standard containing
6.68 3 109 EBV particles per ml (EBV B95-8; Advanced Biotechnologies In-
corporated, Columbia, Md.), as determined by electron microscopy, was used.
Serial half-log dilutions of this standard, ranging from 107 to 10 copies per ml,
were made to characterize the linearity, precision, specificity, and sensitivity of
the TaqMan assay.
For the preparation of the standard curve for the routine TaqMan runs, the
PCR product of 74 bp was directly cloned into a pCRII vector (InVitrogen, Leek,
The Netherlands) and was transformed into the appropriate bacterial strain. The
colonies that were obtained were prescreened by PCR to confirm the size of the
insert. Plasmid DNA was isolated on the Vistra Labstation (Amersham Phar-
macia Biotech, The Netherlands) and was isolated in bulk. The standard curve
made from the plasmid was calibrated with the EBV EM standards and was
routinely made in duplicate with a range equivalent to from 100 to 107 copies per
ml. It was shown that the slope for the plasmid standard was not significantly
different from the slope obtained with the EBV EM standard (P , 0.0001) (data
not shown).
Statistics. The standard curve was created automatically with ABI 7700 Se-
quence Detection System software by plotting the Ct values against each stan-
dard of known concentration. This Ct value was also used for calculation of the
intra- and interassay coefficients of (CVs) variation for the technique. Logarith-
mic transformation of the readings of the different assays was carried out for
comparison of the isolation procedures. x-y scatter diagrams were drawn, and the
correlation coefficients (r2) or Spearman correlation (r) was determined and
linear regression analysis was done by using the statistical functions of SPSS
(version 8.0) software. Student’s t test was used for comparison of the EBV DNA
copy numbers in each group analyzed.
RESULTS
The limit of detection by both extraction methods was de-
termined with half-log dilutions of the EBV EM standard.
Both assays were used in an identical format, in which 100 ml
of patient material was used as input, while the DNA was
eluted in 100 ml of RNase- and DNase-free water. Both assays
were able to detect viral DNA over a linear span of between
100 and 107 copies per ml (Fig. 1). Statistical analysis of the
standard curves over this range showed that both methods
were linear with an r2 value of a minimum of 0.98. Further-
more, the slopes of both standard curves were not significantly
different (P , 0.0001; 95% confidence interval, 20.196 to
0.245). However, the average Ct values obtained by the extrac-
tion method described by Boom et al. (1) were 1.44 lower over
the whole linear range (P , 0.0001) than those obtained with
the High Pure Viral Nucleic Acid extraction kit. This shows
that the efficiency of the extraction step was better for the
method described by Boom et al. (1), as also indicated by the
fact that the 50 copies per ml of the dilution were detected in
all eight replicates, whereas 50 copies per ml were detected in
only one of eight replicates with the adapted High Pure Viral
Nucleic Acid extraction kit. Both methods were unable, how-
ever, to detect 10 copies of the EBV EM standard per ml used
in the formats described above.
A precision study for both extraction methods was per-
formed by evaluating serial half-log dilutions of the EBV EM
standard ranging from 50 to 107 copies per ml in originally
EBV-negative serum. The Ct values obtained were used for the
calculation. The study was carried out over 3 consecutive days,
and two sets of independent isolations were performed. A total
of eight replicates of the 12 dilutions for both extraction meth-
ods were tested on each day. Again, only the method of Boom
et al. (1) was able to detect EBV in the sample with 50 copies
per ml. The assay exhibited a very good total precision
throughout the range of the numbers of EBV DNA copies in
the EBV-positive samples, with CVs ranging from 0.7 to
11.7%. The relatively high CV (11.7%) was due to the inability
to detect 100 copies per ml in one of the eight replicates by the
method with the High Pure Viral Nucleic Acid extraction kit.
The average CV for the High Pure Viral Nucleic Acid extrac-
tion kit was 2.37% (range, 1.1 to 11.7%), and that for the
method of Boom et al. was 1.56% (range, 0.7 to 7.0%). There
was no difference in between-day variation and within-run vari-
ation or within the independent isolations (data not shown).
We furthermore evaluated whether both extraction methods
were able to remove efficiently the inhibitory effect of heparin
on the PCR-based assay. Therefore, four dilutions of the EBV
EM standard were made in heparin- or EDTA-treated plasma;
the dilutions ranged from 500 to 107 copies per ml. The effi-
ciencies of isolation and amplification by the method of Boom
et al. (1) were almost identical whether EDTA-treated or he-
parin-treated plasma was used (Fig. 2), with the variation being
less than twofold. However, with the High Pure Viral Nucleic
Acid extraction kit, the efficiency was reduced between 12- and
200-fold when heparin-treated plasma samples were compared
with EDTA-treated plasma samples. EBV could not be de-
tected in the heparin-treated plasma sample with 500 copies
FIG. 1. Standard curve for TaqMan PCR. Serial dilutions of the EBV EM
standard ranging from 50 to 107 copies per ml were made. Extraction was
performed by the method of Boom et al. (1) (triangles; Spearman correlation
coefficient, 0.997) or the method with the High Pure Viral Nucleic Acid kit
(squares; Spearman correlation coefficient, 0.998) as a matrix. Equal volumes of
input and output material (100 ml) were used. The Ct values, which correspond
to the PCR cycle number in which the value is above the threshold limit, are
plotted against the calculated number of particles counted by electron micros-
copy.
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per ml. Use of EDTA is much easier than the use of heparinase
I, which degrades heparin and involves another incubation step
(13). This experiment also confirms again that the method of
Boom et al. (1) is able to extract the EBV DNA more effi-
ciently than the High Pure Viral Nucleic Acid extraction kit, as
indicated by the lower Ct value.
The analytical specificity of the assay was determined by
analyzing DNAs from other human herpesviruses (herpes sim-
plex virus types 1 and 2, varicella-zoster virus, cytomegalovirus,
and human herpesviruses 6, 7, and 8), as well as from other
viruses routinely used in the laboratory for DNA or RNA
analysis (hepatitis B, C, and G viruses and human papilloma-
virus). All these samples yielded results below the detection
level of 100 copies per ml or a Ct value of 42.
DISCUSSION
To demonstrate that the TaqMan-based assay described
here could be used to detect EBV DNA in clinical samples and
to determine the baseline value for plasma EBV DNA levels in
different groups, we evaluated clinical samples from 100
healthy individuals, 22 patients with IM, a cohort of 109 asymp-
tomatic immunosuppressed solid-organ transplant patients,
and 10 patients with a confirmed diagnosis of PTLD. The
results are summarized in Table 1. For this evaluation, samples
were analyzed in duplicate with the High Pure Viral Nucleic
Acid extraction kit, which has a cutoff value of 100 copies per
ml. As expected, EBV DNA could not be detected in the
plasma of any of the 100 healthy individuals. We were able to
detect low levels of EBV DNA in 21 of 109 solid-organ trans-
plant patients (19.2%), with a mean of 440 copies per ml
(range, ,100 to 12,000 copies per ml). This was, however, not
statistically different from the value for the control group (P 5
0.19). We could detect a signal for EBV DNA in 16 of 22
samples (72.7%) from IM patients, with a mean value of 6,400
copies per ml (range, ,100 to 45,000 copies per ml). This EBV
DNA load was significantly higher than that for the control
group (P , 0.006).
It has been shown previously that the presence of EBV DNA
in plasma is diagnostic for a clinical EBV infection (3, 4, 17).
EBV DNA should be absent from the plasma of healthy indi-
viduals. Using a sensitive detection method like PCR, however,
one is able to detect viral genomes in peripheral blood mono-
nuclear cells (PBMCs) of healthy controls (7, 17; unpublished
data). In the study of Kimura et al. (7), a viral load of 315
copies per mg of PBMC DNA was set as a criterion for distin-
guishing a latent infection from a symptomatic EBV infection
or EBV-related disease.
An EBV DNA load could be determined for only 16 of 22
samples from IM patients with a primary infection. It can be
concluded from the data of Yamamoto et al. (17) that this is
due to the time point of sampling. Also, the group of Kimura
et al. (7) did not find a positive EBV DNA signal in PBMCs
from all of their IM patients analyzed.
We expected to be able to find active replication of EBV in
the group of immunocompromised solid-organ transplant pa-
tients due to the immunosuppression. We were able to detect
EBV DNA in the plasma of 19.2% of the patients analyzed.
None of these patients had clinical signs of an active EBV
infection or EBV-related disease. However, one could expect
specifically that reactivation of EBV is more likely to occur in
this group than in healthy individuals. Our findings indicate
that plasma EBV loads of up to 12,000 copies of DNA per ml
can easily be detected in our cohort with no indications of an
EBV-related disease. However, no data are available on the
longitudinal follow-up period required to determine whether
several EBV reactivation periods can be detected in this group.
We confirm the data of Kimura et al. (7), who also detected
EBV DNA in PBMCs from 14% of posttransplant patients
with no signs of EBV-related disease.
The group for which the use of a quantitative PCR should be
most useful are patients with a diagnosis of PTLD. In the
group of 10 transplant patients diagnosed with PTLD but for
whom treatment such as reduction of immunosuppressive ther-
apy, or the initiation of antiviral treatment was not initiated,
the mean EBV load in plasma was 544,750 copies per ml
(range, 74,000 to 3.2 3 106 copies per ml), which is significantly
higher than those in the groups mentioned above (P , 0.0001).
However, there is a difference between a clinical diagnosis of
PTLD and the viral load at which one should be aware that
PTLD is developing. Therefore, we suggest that routine mon-
itoring of patients at risk for EBV-related proliferative disease
will allow determination of whether there is a progression of
this life-threatening disease from a virological point of view.
FIG. 2. Detection of EBV EM standard dilutions made in heparin-treated
plasma (dashed line) or EDTA-treated plasma (solid line). From these EBV
dilutions, ranging from 500 to 107 copies per ml, DNA was isolated by the
extraction method of Boom et al. (1), which uses Celite (n ) to absorb the DNA,
as well as by the method with the High Pure Viral Nucleic Acid kit (Roche
Diagnostic) (F). The extracted DNA was quantified by the TaqMan assay.
TABLE 1. Quantitation of EBV DNA load by TaqMan analysis
Patient group No. of patients % Positive Mean EBV DNA load (copies/mla [range])
Healthy donors 100 0 ,100
Solid-organ transplant patients 109 19.2 440 (,100–12,000)b
IM patients 22 72.7 6,400 (,100–45,000)c
PTLD patients 10 100 544,750 (74,000–3,200,000)d
a All values are averages of two independent experiments.
b Not statistically different from healthy control group (P 5 0.19).
c Statistically different from control group (P , 0.006) and solid organ transplant group (P , 0.0001).
d Statistically different from all other groups studied (P , 0.0001).
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In summary, by use of the real-time PCR technique de-
scribed here, an easy-to-use and highly reproducible technique
is available for evaluation of the significance of EBV DNA in
plasma samples in immunosuppressed patients. Depending on
the isolation method used, inhibition by heparin of the ampli-
fication reaction can be eliminated. In this study we also con-
firm the data presented by others (3, 4, 17) that there is a
relation between plasma EBV DNA levels and EBV-related
diseases. However, active replication could also be detected in
patients without clinical EBV-related disease. Future studies
must define the cutoff levels at which treatment of patients at
risk for PTLD should be initiated. The technique can then be
used to monitor the effect of antiviral therapy on EBV,
whether this is by infusion of donor T cells, a change of im-
munosuppressive therapy, or provision of nucleoside ana-
logues to inhibit EBV replication.
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